These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 19799828

  • 1. Adalimumab in the treatment of psoriasis: pooled efficacy and safety results from three pivotal studies.
    Papp K, Okun M, Vender R.
    J Cutan Med Surg; 2009; 13 Suppl 2():S58-66. PubMed ID: 19799828
    [Abstract] [Full Text] [Related]

  • 2. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
    Leonardi C, Langley RG, Papp K, Tyring SK, Wasel N, Vender R, Unnebrink K, Gupta SR, Valdecantos WC, Bagel J.
    Arch Dermatol; 2011 Apr; 147(4):429-36. PubMed ID: 21173304
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
    Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM.
    Am J Clin Dermatol; 2011 Feb 01; 12(1):51-62. PubMed ID: 21110526
    [Abstract] [Full Text] [Related]

  • 4. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, Bianchi L, Chimenti S.
    J Am Acad Dermatol; 2007 Aug 01; 57(2):269-75. PubMed ID: 17574299
    [Abstract] [Full Text] [Related]

  • 5. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
    Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K.
    J Am Acad Dermatol; 2008 Jan 01; 58(1):106-15. PubMed ID: 17936411
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
    Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, Li S, Shen YK, Blauvelt A.
    JAMA Dermatol; 2018 Jun 01; 154(6):676-683. PubMed ID: 29799960
    [Abstract] [Full Text] [Related]

  • 7. Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis.
    Bagel J.
    J Drugs Dermatol; 2011 Apr 01; 10(4):366-71. PubMed ID: 21455546
    [Abstract] [Full Text] [Related]

  • 8. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
    Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA.
    J Dermatolog Treat; 2007 Apr 01; 18(1):25-31. PubMed ID: 17365264
    [Abstract] [Full Text] [Related]

  • 9. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
    Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen YK, Szapary P, Randazzo B, Reich K.
    N Engl J Med; 2015 Jul 09; 373(2):136-44. PubMed ID: 26154787
    [Abstract] [Full Text] [Related]

  • 10. Adalimumab for the treatment of psoriasis.
    Turner D, Picot J, Cooper K, Loveman E.
    Health Technol Assess; 2009 Sep 09; 13 Suppl 2():49-54. PubMed ID: 19804689
    [Abstract] [Full Text] [Related]

  • 11. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study.
    Asahina A, Nakagawa H, Etoh T, Ohtsuki M, Adalimumab M04-688 Study Group.
    J Dermatol; 2010 Apr 09; 37(4):299-310. PubMed ID: 20507398
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
    Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM.
    J Am Acad Dermatol; 2010 Sep 09; 63(3):448-56. PubMed ID: 20605254
    [Abstract] [Full Text] [Related]

  • 13. Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital.
    Noda S, Mizuno K, Adachi M.
    J Dermatol; 2012 Mar 09; 39(3):265-8. PubMed ID: 22126280
    [Abstract] [Full Text] [Related]

  • 14. Adalimumab: in plaque psoriasis.
    Croom KF, McCormack PL.
    Am J Clin Dermatol; 2009 Mar 09; 10(1):43-50. PubMed ID: 19170412
    [Abstract] [Full Text] [Related]

  • 15. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
    Van Lümig PP, Lecluse LL, Driessen RJ, Spuls PI, Boezeman JB, van de Kerkhof PC, De Jong EM.
    Br J Dermatol; 2010 Oct 09; 163(4):838-46. PubMed ID: 20649798
    [Abstract] [Full Text] [Related]

  • 16. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study.
    Revicki DA, Menter A, Feldman S, Kimel M, Harnam N, Willian MK.
    Health Qual Life Outcomes; 2008 Oct 02; 6():75. PubMed ID: 18831744
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.
    Ortonne JP, Chimenti S, Reich K, Gniadecki R, Sprøgel P, Unnebrink K, Kupper H, Goldblum O, Thaçi D.
    J Eur Acad Dermatol Venereol; 2011 Sep 02; 25(9):1012-20. PubMed ID: 21214631
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
    Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB.
    J Am Acad Dermatol; 2017 Mar 02; 76(3):405-417. PubMed ID: 28057360
    [Abstract] [Full Text] [Related]

  • 19. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.
    Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, Heffernan M, Miller B, Hamlin R, Lim L, Zhong J, Hoffman R, Okun MM.
    J Am Acad Dermatol; 2006 Oct 02; 55(4):598-606. PubMed ID: 17010738
    [Abstract] [Full Text] [Related]

  • 20. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.
    Papp K, Crowley J, Ortonne JP, Leu J, Okun M, Gupta SR, Gu Y, Langley RG.
    Br J Dermatol; 2011 Feb 02; 164(2):434-41. PubMed ID: 21083543
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.